<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:12:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8897752" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8897752</identifier>
        <datestamp>2022-03-22</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8897752</article-id>
              <article-id pub-id-type="pmcid">PMC8897752</article-id>
              <article-id pub-id-type="pmc-uid">8897752</article-id>
              <article-id pub-id-type="pmid">35244702</article-id>
              <article-id pub-id-type="pmid">35244702</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.1048</article-id>
              <article-id pub-id-type="publisher-id">zoi220058</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Genetics and Genomics</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Effect of Disclosing Genetic Risk for Kidney Failure on Patients</alt-title>
                <alt-title alt-title-type="running-head">Effect of Disclosing Genetic Risk for Kidney Failure on Patients</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Nadkarni</surname>
                    <given-names>Girish N.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi220058aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fei</surname>
                    <given-names>Kezhen</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi220058aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220058aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramos</surname>
                    <given-names>Michelle A.</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref rid="zoi220058aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220058aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hauser</surname>
                    <given-names>Diane</given-names>
                  </name>
                  <degrees>MPA</degrees>
                  <xref rid="zoi220058aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bagiella</surname>
                    <given-names>Emilia</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220058aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ellis</surname>
                    <given-names>Stephen B.</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sanderson</surname>
                    <given-names>Saskia</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scott</surname>
                    <given-names>Stuart A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi220058aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="zoi220058aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sabin</surname>
                    <given-names>Tatiana</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref rid="zoi220058aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220058aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Madden</surname>
                    <given-names>Ebony</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220058aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220058aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pollak</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220058aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Calman</surname>
                    <given-names>Neil</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220058aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220058aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bottinger</surname>
                    <given-names>Erwin P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220058aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi220058aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Horowitz</surname>
                    <given-names>Carol R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi220058aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi220058aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220058aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi220058aff1"><label>1</label>Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York</aff>
              <aff id="zoi220058aff2"><label>2</label>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York</aff>
              <aff id="zoi220058aff3"><label>3</label>Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, New York</aff>
              <aff id="zoi220058aff4"><label>4</label>Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, New York</aff>
              <aff id="zoi220058aff5"><label>5</label>Institute for Family Health, New York, New York</aff>
              <aff id="zoi220058aff6"><label>6</label>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York</aff>
              <aff id="zoi220058aff7"><label>7</label>Sema4, A Mount Sinai Venture, Stamford, Connecticut</aff>
              <aff id="zoi220058aff8"><label>8</label>National Human Genome Research Institute, Bethesda, Maryland</aff>
              <aff id="zoi220058aff9"><label>9</label>Department of Public Health Sciences, Loyola University Medical School, Maywood, Illinois</aff>
              <aff id="zoi220058aff10"><label>10</label>Division of Nephrology, Harvard Medical School, Boston, Massachusetts</aff>
              <aff id="zoi220058aff11"><label>11</label>Digital Health Center, Hasso Plattner Institute, Potsdam, Germany</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> December 29, 2021.</p>
                <p content-type="published-online"><bold>Published:</bold> March 4, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2022.1048</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2022 Nadkarni GN et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi220058cor1"><bold>Corresponding Authors:</bold> Girish N. Nadkarni, MD, MPH (<email xlink:href="girish.nadkarni@mountsinai.org">girish.nadkarni@mountsinai.org</email>), and Carol R. Horowitz, MD, MPH (<email xlink:href="carol.horowitz@mssm.edu">carol.horowitz@mssm.edu</email>), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1077, New York, NY 10029.</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Nadkarni and Horowitz had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Bottinger and Horowitz contributed equally to this manuscript.</p>
                <p><italic>Concept and design:</italic> Fei, Bagiella, Sanderson, Madden, Pollak, Calman, Horowitz.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Nadkarni, Fei, Ramos, Hauser, Ellis, Scott, Sabin, Cooper, Bottinger, Horowitz.</p>
                <p><italic>Drafting of the manuscript:</italic> Nadkarni, Ramos, Bagiella, Sabin, Horowitz.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Fei, Hauser, Ellis, Sanderson, Scott, Madden, Cooper, Pollak, Calman, Bottinger, Horowitz.</p>
                <p><italic>Statistical analysis:</italic> Fei, Bagiella, Horowitz.</p>
                <p><italic>Obtained funding:</italic> Horowitz.</p>
                <p><italic>Administrative, technical, or material support:</italic> Ramos, Hauser, Ellis, Sanderson, Scott, Sabin, Madden, Cooper, Calman, Horowitz.</p>
                <p><italic>Supervision:</italic> Nadkarni, Sanderson, Pollak, Bottinger, Horowitz.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Nadkarni reported receiving personal fees from Renalytix, being a cofounder and having equity in Renalytix, and being a member of the scientific advisory board of Renalyti and a cofounder of Pensieve Health. Mss Ramos and Hauser and Dr Horowitz reported receiving grants from the National Human Genome Research Institute (NHGRI)/National Institutes of Health (NIH) during the conduct of the study. Dr Bagiella reported receiving grants from the NIH during the conduct of the study. Dr Scott reported being a paid consultant of Sema4. Dr Pollak reported receiving grants and personal fees from Vertex and having equity in Apolo1Bio outside the submitted work; in addition, Dr Pollak had a patent for US20200399702A1 issued. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study is supported by grant U01HG007278 from the NHGRI and grant UL1TR000067 from the National Center for Advancing Translational Sciences. Dr Nadkarni is supported by grants R01DK127139 and R01HL155915 from the NIH.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> Dr Ogedegbe is an Associate Editor of <italic>JAMA Network Open</italic>, but he was not involved in any of the decisions regarding review of the manuscript or its acceptance.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI220058-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p>
                <p><bold>Additional Contributions:</bold> The authors would also like to thank the Genetic Testing to Understand and Address Renal Disease Disparities (GUARDD) team of academic, community, clinical partners, study coordinators, and staff at study sites, and their partners in the Implementing Genomics in Practice (IGNITE) Network, a consortium of genomic medicine pilot demonstration projects funded and guided by the NHGRI, for their valuable contributions to this project. We would like to thank Linda Cameron, PhD, University of California, Merced, Howard Leventhal, PhD, Rutgers University, and Gbenga Ogedegbe, MD, MPH, NYU Grossman School of Medicine, for their input. They were compensated as consultants to the study.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-03-04T10:00">
                <day>4</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>4</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>5</volume>
              <issue>3</issue>
              <elocation-id>e221048</elocation-id>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Nadkarni GN et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e221048.pdf">jamanetwopen-e221048.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.1048"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi220058-1">
                  <title>Question</title>
                  <p>What are the effects of testing and disclosing the genetic results for <italic>APOL1</italic> on patients of African ancestry with hypertension and their clinicians?</p>
                </sec>
                <sec id="ab-zoi220058-2">
                  <title>Findings</title>
                  <p>In this randomized clinical trial of 2050 patients of African ancestry with hypertension without chronic kidney disease in which genetic testing results were disclosed to patients and clinicians, patients with high-risk <italic>APOL1</italic> genotypes had greater improvement in blood pressure from baseline and more lifestyle changes (better dietary and exercise habits) compared with patients with low-risk <italic>APOL1</italic> genotypes or waiting list control patients.</p>
                </sec>
                <sec id="ab-zoi220058-3">
                  <title>Meaning</title>
                  <p>Disclosing <italic>APOL1</italic> genetic testing results to patients of African ancestry with hypertension and to their clinicians was associated with a greater reduction in blood pressure, kidney disease screening, and self-reported behavior changes in those with high-risk <italic>APOL1</italic> genotypes.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi220058-4">
                  <title>Importance</title>
                  <p>Risk variants in the apolipoprotein L1 (<italic>APOL1</italic> [OMIM <ext-link xlink:href="http://omim.org/603743" ext-link-type="uri">603743</ext-link>]) gene on chromosome 22 are common in individuals of West African ancestry and confer increased risk of kidney failure for people with African ancestry and hypertension. Whether disclosing <italic>APOL1</italic> genetic testing results to patients of African ancestry and their clinicians affects blood pressure, kidney disease screening, or patient behaviors is unknown.</p>
                </sec>
                <sec id="ab-zoi220058-5">
                  <title>Objective</title>
                  <p>To determine the effects of testing and disclosing <italic>APOL1</italic> genetic results to patients of African ancestry with hypertension and their clinicians.</p>
                </sec>
                <sec id="ab-zoi220058-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018. Patients were randomly assigned to undergo immediate (intervention) or delayed (waiting list control group) <italic>APOL1</italic> testing in a 7:1 ratio. Statistical analysis was performed from May 1, 2018, to July 31, 2020.</p>
                </sec>
                <sec id="ab-zoi220058-7">
                  <title>Interventions</title>
                  <p>Patients randomly assigned to the intervention group received <italic>APOL1</italic> genetic testing results from trained staff; their clinicians received results through clinical decision support in electronic health records. Waiting list control patients received the results after their 12-month follow-up visit.</p>
                </sec>
                <sec id="ab-zoi220058-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Coprimary outcomes were the change in 3-month systolic blood pressure and 12-month urine kidney disease screening comparing intervention patients with high-risk <italic>APOL1</italic> genotypes and those with low-risk <italic>APOL1</italic> genotypes. Secondary outcomes compared these outcomes between intervention group patients with high-risk <italic>APOL1</italic> genotypes and controls. Exploratory analyses included psychobehavioral factors.</p>
                </sec>
                <sec id="ab-zoi220058-9">
                  <title>Results</title>
                  <p>Among 2050 randomly assigned patients (1360 women [66%]; mean [SD] age, 53 [10] years), the baseline mean (SD) systolic blood pressure was significantly higher in patients with high-risk <italic>APOL1</italic> genotypes vs those with low-risk <italic>APOL1</italic> genotypes and controls (137 [21] vs 134 [19] vs 133 [19] mm Hg; <italic>P</italic> = .003 for high-risk vs low-risk <italic>APOL1</italic> genotypes; <italic>P</italic> = .001 for high-risk <italic>APOL1</italic> genotypes vs controls). At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk <italic>APOL1</italic> genotypes vs those with low-risk <italic>APOL1</italic> genotypes (6 [18] vs 3 [18] mm Hg; <italic>P</italic> = .004) and controls (6 [18] vs 3 [19] mm Hg; <italic>P</italic> = .01). At 12 months, there was a 12% increase in urine kidney disease testing among patients with high-risk <italic>APOL1</italic> genotypes (from 39 of 234 [17%] to 68 of 234 [29%]) vs a 6% increase among those with low-risk <italic>APOL1</italic> genotypes (from 278 of 1561 [18%] to 377 of 1561 [24%]; <italic>P</italic> = .10) and a 7% increase among controls (from 33 of 255 [13%] to 50 of 255 [20%]; <italic>P</italic> = .01). In response to testing, patients with high-risk <italic>APOL1</italic> genotypes reported more changes in lifestyle (a subjective measure that included better dietary and exercise habits; 129 of 218 [59%] vs 547 of 1468 [37%]; <italic>P</italic> &lt; .001) and increased blood pressure medication use (21 of 218 [10%] vs 68 of 1468 [5%]; <italic>P</italic> = .005) vs those with low-risk <italic>APOL1</italic> genotypes; 1631 of 1686 (97%) declared they would get tested again.</p>
                </sec>
                <sec id="ab-zoi220058-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this randomized clinical trial, disclosing <italic>APOL1</italic> genetic testing results to patients of African ancestry with hypertension and their clinicians was associated with a greater reduction in systolic blood pressure, increased kidney disease screening, and positive self-reported behavior changes in those with high-risk genotypes.</p>
                </sec>
                <sec id="ab-zoi220058-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02234063" ext-link-type="uri">NCT02234063</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized clinical trial determines the effects of testing and disclosing <italic>APOL1</italic> genetic results on patients of African ancestry with hypertension and their clinicians.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI220058">
              <title>Introduction</title>
              <p>Chronic kidney disease (CKD) affects 26 million US adults.<sup><xref rid="zoi220058r1" ref-type="bibr">1</xref></sup> Individuals of African ancestry have a higher risk of CKD and end-stage kidney disease than individuals with European ancestry owing to social determinants, clinical factors, and health system factors.<sup><xref rid="zoi220058r1" ref-type="bibr">1</xref>,<xref rid="zoi220058r2" ref-type="bibr">2</xref>,<xref rid="zoi220058r3" ref-type="bibr">3</xref></sup> Race and ethnicity are social constructs, but ancestry has some biological underpinnings. High-risk genotypes at the apolipoprotein L1 (APOL1) locus confer a 5-fold to 10-fold increased risk for CKD and end-stage kidney disease attributed to hypertension, although this risk increment is attenuated among individuals with diabetes.<sup><xref rid="zoi220058r4" ref-type="bibr">4</xref>,<xref rid="zoi220058r5" ref-type="bibr">5</xref>,<xref rid="zoi220058r6" ref-type="bibr">6</xref></sup> High-risk variants of <italic>APOL1</italic> (OMIM <ext-link xlink:href="http://omim.org/603743" ext-link-type="uri">603743</ext-link>) on chromosome 22 are found in 1 of 7 people of African ancestry but are nearly absent in people of European ancestry<sup><xref rid="zoi220058r7" ref-type="bibr">7</xref></sup> because they confer resistance to trypanosomal infection and are subject to positive selection in West Africa.<sup><xref rid="zoi220058r8" ref-type="bibr">8</xref>,<xref rid="zoi220058r9" ref-type="bibr">9</xref></sup></p>
              <p>Although it is important to avoid overstating the importance of genetic contributions to chronic disease disparities and to acknowledge that social determinants of health are the critical determinants of disparities,<sup><xref rid="zoi220058r10" ref-type="bibr">10</xref></sup> racial and ethnic minority populations should not be the last to benefit from scientific advances, including genetic discoveries. There is increasing interest in incorporating genetic testing into primary care.<sup><xref rid="zoi220058r11" ref-type="bibr">11</xref>,<xref rid="zoi220058r12" ref-type="bibr">12</xref>,<xref rid="zoi220058r13" ref-type="bibr">13</xref></sup> The <italic>APOL1</italic> risk genotype is common and confers high risk for a serious chronic disease in people of African ancestry, who are disproportionately burdened by chronic diseases, and thus it may be important to incorporate genetic testing into clinical care.<sup><xref rid="zoi220058r11" ref-type="bibr">11</xref>,<xref rid="zoi220058r12" ref-type="bibr">12</xref></sup> Blood pressure (BP) control reduces kidney function deterioration,<sup><xref rid="zoi220058r14" ref-type="bibr">14</xref></sup> but people of African ancestry have the highest age-adjusted prevalence of hypertension and the lowest rates of blood pressure control.<sup><xref rid="zoi220058r15" ref-type="bibr">15</xref></sup> Kidney function tests, including urine microalbumin testing, aid in risk stratification and clinical staging but are underused among patients at high risk of CKD, especially patients of African ancestry.<sup><xref rid="zoi220058r16" ref-type="bibr">16</xref></sup></p>
              <p>Stricter BP control may have a mortality benefit for persons with high-risk <italic>APOL1</italic> genotypes,<sup><xref rid="zoi220058r17" ref-type="bibr">17</xref></sup> but little is known about whether testing patients for <italic>APOL1</italic> risk will affect clinical care processes, including appropriate kidney disease screening, or improve outcomes, such as BP control or incident CKD, or how patients will respond to testing. Effective communication of genetic risk to clinicians supported by clinical decision support in electronic health records (EHRs), as well as to patients, may be useful because it has been useful for hypertension control in general.<sup><xref rid="zoi220058r18" ref-type="bibr">18</xref>,<xref rid="zoi220058r19" ref-type="bibr">19</xref></sup></p>
              <p>Testing of <italic>APOL1</italic> status is being used in niche clinical settings, including for evaluation of living kidney donors.<sup><xref rid="zoi220058r20" ref-type="bibr">20</xref>,<xref rid="zoi220058r21" ref-type="bibr">21</xref></sup> To our knowledge, there are no proven interventions at this time, but there appears to be consensus that the presence of high-risk alleles alone does not necessarily lead to kidney failure. Other factors, such as social determinants of health or control or lack of control of BP, may influence the clinical course of persons with high-risk alleles. To determine whether risk disclosure would affect BP and kidney testing, researchers collaborated with a genomics stakeholder board (consisting of patients, clinicians, advocates, and health system leaders) to conduct the Genetic Testing to Understand and Address Renal Disease Disparities (GUARDD) trial to study the effects of incorporating <italic>APOL1</italic> genotype information into primary care management of adults of African ancestry with hypertension.</p>
            </sec>
            <sec id="H1-2-ZOI220058">
              <title>Methods</title>
              <sec id="H2-1-ZOI220058">
                <title>Study Design and Participants</title>
                <p>This randomized clinical trial (protocol in <xref rid="note-ZOI220058-1-s" ref-type="supplementary-material">Supplement 1</xref>) enrolled patients from 15 academic, community, and safety-net practices in 2 health systems in New York City from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018.<sup><xref rid="zoi220058r22" ref-type="bibr">22</xref></sup> Inclusion criteria were self-identified African ancestry, being 18 to 70 years of age, hypertension EHR diagnosis and/or taking antihypertensive medications and/or 2 systolic BP (SBP) readings greater than 140 mm Hg at least 6 months apart, community dwelling, English speaking, and receiving primary care at a participating site in the past year. Exclusion criteria were diabetes, CKD, pregnancy, moving away during the study period, and cognitive impairment. This study was approved by the Icahn School of Medicine for Family Health Institutional Review Board. All participants provided written informed consent. This study followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.<sup><xref rid="zoi220058r23" ref-type="bibr">23</xref></sup></p>
              </sec>
              <sec id="H2-2-ZOI220058">
                <title>Recruitment of Participants</title>
                <p>We used EHRs to identify patients potentially meeting inclusion criteria. Coordinators mailed these patients a recruitment letter, telephoned those who did not decline, screened them, and scheduled enrollment. We placed study flyers in waiting rooms, intercepted potentially eligible patients at clinics when they were hard to reach, and encouraged clinicians to refer patients.</p>
              </sec>
              <sec id="H2-3-ZOI220058">
                <title>Randomization and Masking</title>
                <p>We randomly assigned patients to immediate vs delayed intervention (waiting list control) in a 7:1 ratio so that the number of patients with 2 high-risk <italic>APOL1</italic> alleles would approximate the number of control patients to optimize study power. We stratified randomization by clinical site.</p>
              </sec>
              <sec id="H2-4-ZOI220058">
                <title>Collection of Data</title>
                <p>During baseline, 3-month, and 12-month study visits, trained coordinators administered a survey ascertaining demographic characteristics, knowledge, attitudes, and behaviors<sup><xref rid="zoi220058r22" ref-type="bibr">22</xref></sup>; measured sitting BP with BpTru BPM-200 digital monitors validated against in-office and 24-hour ambulatory BPs; and averaged the second and third of 3 measurements.<sup><xref rid="zoi220058r24" ref-type="bibr">24</xref></sup> We identified urine protein to creatinine ratio and microalbumin to creatinine ratio testing in EHRs up to 12 months before (baseline) and for 12 months after (postintervention) randomization. For genetic testing at baseline for intervention patients and at 12 months for controls, coordinators collected venous blood samples (or saliva samples via Oragene kits if needed).</p>
              </sec>
              <sec id="H2-5-ZOI220058">
                <title><italic>APOL1</italic> Testing, Return of Results, and Clinical Decision Support</title>
                <p>Our clinical decision support engine provided privacy-protected data flow and real-time communication between the EHR, genetic testing laboratory, and study team.<sup><xref rid="zoi220058r22" ref-type="bibr">22</xref></sup> A validated assay interrogated <italic>APOL1</italic> G1 and G2 alleles<sup><xref rid="zoi220058r7" ref-type="bibr">7</xref></sup> in a Clinical Laboratory Improvement Amendments, College of American Pathologists–accredited clinical laboratory. Coordinators trained and supervised by a senior genetic counselor returned results to ensure that all patients would receive standardized information in a timely manner. Patients received a result of high-risk <italic>APOL1</italic> genotypes if they were homozygous or compound heterozygous carriers of G1 and/or G2 alleles, and patients received a result of low-risk <italic>APOL1</italic> genotypes if they were heterozygous G1 or G2 or homozygous wild-type allele carriers. Coordinators returned results of low-risk <italic>APOL1</italic> genotypes over the telephone and results of high-risk <italic>APOL1</italic> genotypes in person, using “teach back” (coordinators asked patients to repeat their explanation in the patients’ own words, and if not correct, coordinators would repeat or reframe the explanation until the patients were correct) to ensure comprehension.<sup><xref rid="zoi220058r25" ref-type="bibr">25</xref></sup> All patients received a scripted message indicating that it is important to control BP for many reasons, including kidney health; were asked if they wanted to speak to or meet with the study’s genetic counselor; and received a low literacy educational booklet with their results.</p>
                <p>Return of results triggered an EHR best practice alert with results that fired once for every primary care professional (PCP) who opened an encounter in the 1-year follow-up period.<sup><xref rid="zoi220058r26" ref-type="bibr">26</xref></sup> Waiting list control patients received the results after their 12-month follow-up visit. The alert included the result, a message that BP control can help forestall kidney failure, the 3 most recent BP readings, and links to information for clinicians and patients with 1-click access and printing. The entire process was informed by formative interviews; developed in partnership with the genomic stakeholder board’s patients, advocates, and clinicians; tailored by and for patients of African ancestry and for low-literate populations; and extensively piloted and revised.<sup><xref rid="zoi220058r27" ref-type="bibr">27</xref></sup></p>
              </sec>
              <sec id="H2-6-ZOI220058">
                <title>Outcomes</title>
                <p>We compared patients with high-risk <italic>APOL1</italic> genotypes with patients with low-risk <italic>APOL1</italic> genotypes for the 2 primary end points: 3-month SBP and 12-month urine albumin screening for kidney disease. Secondary outcomes included differences in SBP and urine testing in an enriched intervention group (patients with high-risk <italic>APOL1</italic> genotypes) vs controls and psychobehavioral patient factors between groups and over time. We did not focus on kidney screening via serum creatinine testing because it is part of routine panels ordered for reasons often unrelated to CKD screening or assessment.</p>
              </sec>
              <sec id="H2-7-ZOI220058">
                <title>Statistical Analysis</title>
                <p>Statistical analysis was performed from May 1, 2018, to July 31, 2020. We used mean (SD) values to describe continuous variables and proportions to describe categorical variables; the <italic>t</italic> test or analysis of variance was used to compare continuous variables, and the χ<sup>2</sup> test or the Fisher exact test was used to compare categorical variables by groups. To test significance of changes within groups over time, we used paired <italic>t</italic> tests for continuous variables and McNemar tests for categorical variables. We used linear mixed models to test the difference in SBP change over time between patients with high-risk <italic>APOL1</italic> genotypes and those with low-risk <italic>APOL1</italic> genotypes by entering the interaction term of time and <italic>APOL1</italic> status and adjusting for confounders, and we used generalized estimating equation methods to test the change in controlled SBP status and kidney function testing over time between patients with high-risk <italic>APOL1</italic> genotypes and those with low-risk <italic>APOL1</italic> genotypes and similarly between patients with high-risk <italic>APOL1</italic> genotypes and controls. Analyses were conducted in SAS, version 9.4 (SAS Institute Inc), and <italic>P</italic> values were from 2-sided tests, with significance set at <italic>P</italic> &lt; .05.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI220058">
              <title>Results</title>
              <p>From November 1, 2014, to November 30, 2016, we approached 5481 patients identified in EHR queries; 2050 (37%) were enrolled, 2783 (51%) were ineligible, 234 (4%) declined, and 412 (8%) were undecided when enrollment finished (<xref rid="zoi220058f1" ref-type="fig">Figure</xref>). Of 2052 enrolled, 2050 were randomized. Participants had a mean (SD) age of 53 (10) years; 1360 of 2050 were women (66%; a similar proportion as in the initial EHR list), 1014 of 2050 (50%) had very low income, 769 of 2050 (38%) had low health literacy, and 530 of 2050 (26%) had very good or excellent self-rated health (<xref rid="zoi220058t1" ref-type="table">Table 1</xref>). We retained 92% (1886 of 2050) at 3 months and 77% (1587 of 2050) at 12 months, with no differences in follow-up rates by study group.<sup><xref rid="zoi220058r28" ref-type="bibr">28</xref></sup> There were no differences in sociodemographic characteristics between intervention and control patients except that control patients had higher educational attainment (more than some college: 162 of 255 [64%] control patients vs 1010 of 1795 [56%] intervention patients). However, patients with high-risk <italic>APOL1</italic> genotypes had significantly higher mean (SD) SBP at baseline (137 [21] mm Hg) than those with low-risk <italic>APOL1</italic> genotypes (134 [19] mm Hg; <italic>P</italic> = .003) and controls (133 [19] mm Hg; <italic>P</italic> = .001) (<xref rid="zoi220058t2" ref-type="table">Table 2</xref>).</p>
              <fig position="float" id="zoi220058f1" fig-type="figure">
                <label>Figure. </label>
                <caption>
                  <title>Enrollment and Randomization of Study Participants</title>
                </caption>
                <graphic xlink:href="jamanetwopen-e221048-g001" position="float"/>
              </fig>
              <table-wrap position="float" id="zoi220058t1">
                <label>Table 1. </label>
                <caption>
                  <title>Characteristics of Patients by Randomization and <italic>APOL1</italic> Status Groups</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="50.55%" span="1"/>
                  <col width="27.99%" span="1"/>
                  <col width="21.46%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Patients, No. (%)</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Delayed intervention, control (n = 255 [12%])</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Intervention (n = 1795 [88%])</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">53 (10)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">53 (10)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">83 (33)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">607 (34)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">172 (67)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1188 (66)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Household income &lt;$30 000/y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">126 (49)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">888 (50)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Education more than some college</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">162 (64)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1010 (56)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Married or living with partner</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">72 (28)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">541 (30)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Insurance</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Private</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">118 (46)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">747 (42)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicaid</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">109 (43)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">821 (46)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14 (5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">126 (7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8 (3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">51 (3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> None</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">50 (3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Charlson Comorbidity Index</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">141 (55)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">925 (52)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">61 (24)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">481 (27)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥2</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">53 (21)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">391 (22)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline mean (SD), mm Hg</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Systolic blood pressure</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">133.8 (19.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">134.2 (19.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diastolic blood pressure</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">85.4 (12.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">86.4 (12.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">33.9 (7.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">32.4 (7.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">High health literacy</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">169 (66)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1112 (62)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Excellent or very good self-reported health</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">64 (25)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">466 (26)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).</p>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="zoi220058t2">
                <label>Table 2. </label>
                <caption>
                  <title>Main Outcome Comparisons Between Randomization and <italic>APOL1</italic> Status Groups</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="25.43%" span="1"/>
                  <col width="9.66%" span="1"/>
                  <col width="13.15%" span="1"/>
                  <col width="11.41%" span="1"/>
                  <col width="17.56%" span="1"/>
                  <col width="12.27%" span="1"/>
                  <col width="10.52%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Control (n = 255 [12%])</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Intervention</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Unadjusted <italic>P</italic> value</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adjusted <italic>P</italic> value<xref rid="zoi220058t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Low-risk genotypes (n = 1561 [76%])</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">High-risk genotypes (n = 234 [11%])</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">High-risk <italic>APOL1</italic> genotypes vs low-risk <italic>APOL1</italic> genotypes</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">High-risk <italic>APOL1</italic> genotypes vs control</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">SBP, mean (SD), mm Hg</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At baseline</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">133 (19)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">134 (19)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">137 (21)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.003</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.03</td>
                      <td rowspan="4" valign="middle" align="left" colspan="1">.02</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At 3 mo</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">131 (19)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">131 (18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">131 (19)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.83</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.92</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Difference in SBP from baseline to 3 mo, mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−3 (18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−3 (18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−6 (18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.004</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>P</italic> value for change over time within group</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Kidney function urine test, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Before randomization</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">33 (13)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">278 (18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">39 (17)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.67</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.25</td>
                      <td rowspan="3" valign="middle" align="left" colspan="1">.24</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After randomization</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">50 (20)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">377 (24)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">68 (29)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.10</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>P</italic> value for change over time within group</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: NA, not applicable; SBP, systolic blood pressure.</p>
                  <fn id="zoi220058t2n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>For blood pressure, the <italic>P</italic> values for the interaction term of time × <italic>APOL1</italic> status were adjusted for age, sex, baseline SBP, body mass index, comorbidity, income, educational level, and marital status among intervention patients from the linear mixed model. For kidney function urine test, <italic>P</italic> values for the interaction term of time × <italic>APOL1</italic> status were adjusted for age, sex, body mass index, insurance, type of clinician (attending physician or fellow, resident, or nurse practitioner), and institution (academic vs community).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="H2-8-ZOI220058">
                <title>Change in SBP at 3 Months</title>
                <p>Although all groups had some decrease in SBP, it was greatest in patients with high-risk <italic>APOL1</italic> genotypes (mean [SD], 6 [18] mm Hg) vs those with low-risk <italic>APOL1</italic> genotypes (mean [SD], 3 [18] mm Hg; <italic>P</italic> = .004) or controls (mean [SD], 3 [18] mm Hg; <italic>P</italic> = .01) (<xref rid="zoi220058t2" ref-type="table">Table 2</xref>). The percentage change in SBP was significantly different between patients with high-risk <italic>APOL1</italic> genotypes (3.6%), those with low-risk <italic>APOL1</italic> genotypes (1.0%; <italic>P</italic> = .003), and controls (1.3%; <italic>P</italic> = .04). After adjustment for age, sex, body mass index, comorbidity, income, educational level, and marital status, the decrease in SBP remained statistically significantly different between patients with high-risk <italic>APOL1</italic> genotypes and those with low-risk <italic>APOL1</italic> genotypes (<italic>P</italic> = .02). The mean (SD) diastolic BP at 3 months was 83.6 (12.3) mm Hg in patients with high-risk <italic>APOL1</italic> genotypes, 83.8 (10.9) mm Hg in those with low-risk <italic>APOL1</italic> genotypes, and 83.7 (10.9) mm Hg in controls. There was no significant difference in SBP at 12 months or in the change in SBP from baseline to 12 months between groups.</p>
              </sec>
              <sec id="H2-9-ZOI220058">
                <title>Urine Testing for Kidney Function at 12 Months</title>
                <p>A similar proportion of patients in all 3 groups had urine protein excretion tests at baseline. At 12 months after the intervention, all 3 groups showed a significant increase in the rate of urine protein testing over time. The most significant increase was seen in patients with high-risk <italic>APOL1</italic> genotypes (12% increase: from 39 of 234 [17%] to 68 of 234 [29%]) compared with those with low-risk <italic>APOL1</italic> genotypes (6% increase: from 278 of 1561 [18%] to 377 of 1561 [24%]) and controls (7% increase: from 33 of 255 [13%] to 50 of 255 [20%]), a difference significant between patients with high-risk <italic>APOL1</italic> genotypes and controls (<italic>P</italic> = .01), although, over time across groups, this difference did not remain statistically significant (<xref rid="zoi220058t2" ref-type="table">Table 2</xref>). Thus, the prespecified urine testing outcome was negative; however, a significant difference was seen for the patients with high-risk <italic>APOL1</italic> genotypes vs controls on nonprespecified analysis.</p>
              </sec>
              <sec id="H2-10-ZOI220058">
                <title>Psychobehavioral Outcomes of Patients</title>
                <p>A total of 1468 of 1561 patients with low-risk <italic>APOL1</italic> genotypes and 218 of 234 patients with high-risk <italic>APOL1</italic> genotypes completed the surveys. Significantly more patients with high-risk <italic>APOL1</italic> genotypes than patients with low-risk <italic>APOL1</italic> genotypes reported making positive lifestyle changes (a subjective measure that included better dietary and exercise habits) after receiving <italic>APOL1</italic> results (129 of 218 [59%] vs 547 of 1468 [37%]; <italic>P</italic> &lt; .001), changing how they take their BP medications (53 of 218 [24%] vs 146 of 1468 [10%]; <italic>P</italic> &lt; .001) and taking BP medications more often (21 of 218 [10%] vs 68 of 1468 [5%]; <italic>P</italic> = .005) (<xref rid="zoi220058t3" ref-type="table">Table 3</xref>). Nearly all patients stated that they had enough information to decide about getting the test, the information was easy to understand, and they would get tested again. Few had negative reactions, but more patients with high-risk <italic>APOL1</italic> genotypes were upset about their results (17 of 218 [8%] vs 15 of 1468 [1%]; <italic>P</italic> &lt; .001) and worried they would develop kidney problems (59 of 218 [27%] vs 249 of 1468 [17%]; <italic>P</italic> &lt; .001). We offered all patients the opportunity to speak to or meet with a genetic counselor at no cost; however, none chose to do so.</p>
                <table-wrap position="float" id="zoi220058t3">
                  <label>Table 3. </label>
                  <caption>
                    <title>Comparison by <italic>APOL1</italic> Status on Patient Psychosocial Behaviors 3 Months After Randomization</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="46.6%" span="1"/>
                    <col width="22.8%" span="1"/>
                    <col width="20.55%" span="1"/>
                    <col width="10.05%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Intervention <italic>APOL1</italic>, No. (%)<xref rid="zoi220058t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Low-risk genotypes (n = 1468)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">High-risk genotypes (n = 218)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Had enough information on getting the test</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1425 (97)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">208 (95)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.28</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Information for test was easy to understand</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1391 (95)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">203 (94)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.42</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Would get tested again</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1420 (97)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">211 (97)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.83</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Made positive lifestyle changes<xref rid="zoi220058t3n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">547 (37)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">129 (59)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Changed how you take BP medication</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">146 (10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (24)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Take BP medication more often</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">68 (5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.005</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviation: BP, blood pressure.</p>
                    <fn id="zoi220058t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>A total of 1468 of 1561 patients with <italic>APOL1</italic> low-risk genotypes and 218 of 234 patients with <italic>APOL1</italic> high-risk genotypes completed the surveys.</p>
                    </fn>
                    <fn id="zoi220058t3n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Lifestyle changes were subjective and included having better dietary and exercise habits.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="H1-4-ZOI220058">
              <title>Discussion</title>
              <p>Chronic kidney disease and its complications are at epidemic levels,<sup><xref rid="zoi220058r29" ref-type="bibr">29</xref>,<xref rid="zoi220058r30" ref-type="bibr">30</xref>,<xref rid="zoi220058r31" ref-type="bibr">31</xref></sup> and BP control is important for reducing the incidence and progression of CKD.<sup><xref rid="zoi220058r32" ref-type="bibr">32</xref></sup> In partnership with the genomics stakeholder board, we recruited and tested adults with self-reported African ancestry and hypertension for <italic>APOL1</italic> alleles that increase the risk of CKD and end-stage kidney disease. We returned genetic test results to them through trained laypersons and to their PCPs via EHR alerts at 15 academic, community, and safety-net practices. Disclosure of <italic>APOL1</italic> genetic risk results led to a greater decrease in SBP among those with high-risk <italic>APOL1</italic> genotypes vs those with low-risk <italic>APOL1</italic> genotypes and among those with high-risk <italic>APOL1</italic> genotypes vs controls, as well as a significantly greater increase in urine kidney disease screening in all groups, especially among patients with high-risk <italic>APOL1</italic> genotypes. Patients had favorable reactions to testing and return of results, and patients with high-risk <italic>APOL1</italic> genotypes reported positive changes in lifestyle and BP medication use compared with patients with low-risk <italic>APOL1</italic> genotypes.</p>
              <p>This trial tested the effects of disclosing <italic>APOL1</italic> genetic results to patients of African ancestry with hypertension and their PCPs. Baseline SBP was higher in patients with high-risk <italic>APOL1</italic> genotypes (as previously reported<sup><xref rid="zoi220058r33" ref-type="bibr">33</xref></sup>), but the SBP absolute and percentage improvement was higher in this group vs those with low-risk <italic>APOL1</italic> genotypes or controls. To our knowledge, few studies disclosing genetic risk of chronic diseases have led to improved outcomes.<sup><xref rid="zoi220058r34" ref-type="bibr">34</xref>,<xref rid="zoi220058r35" ref-type="bibr">35</xref></sup> Our findings may be due to the use of EHR alerts, which have previously shown efficacy,<sup><xref rid="zoi220058r18" ref-type="bibr">18</xref>,<xref rid="zoi220058r19" ref-type="bibr">19</xref></sup> along with disclosure of genetic results to patients. The magnitude of SBP improvement was small, but we did not provide specific BP target recommendations or BP-lowering strategies to clinicians or patients; future programs may show more benefit with more intense BP-lowering efforts. The SBP improvement may also be the result of the change in behaviors among the patients with high-risk <italic>APOL1</italic> genotypes. Health behavior changes were small and, although statistically significant, may have been clinically not meaningful. The increase in urine screening across all groups may be because physicians were aware of being part of a clinical trial and thus may have changed their test-ordering patterns in response. However, this outcome was modified by an awareness of patients’ genetic risk, with a higher increase in kidney disease screening among patients with high-risk <italic>APOL1</italic> genotypes vs those with low-risk <italic>APOL1</italic> genotypes.</p>
              <p>Translational genomics and clinical informatics may play increasing roles in primary care–based chronic disease prevention and control efforts, but the effect of returning results needs to be tested in rigorous randomized clinical trials. Primary care professionals are central to helping patients understand and address risk and interactions between clinical, genetic, and environmental factors, and they will likely be crucial in efforts to minimize the risk and maximize the benefit of genetic testing in diverse populations and settings.<sup><xref rid="zoi220058r36" ref-type="bibr">36</xref></sup> Thus, return of genetic risk results to PCPs with clear care plans, targeted education, and recommended clinical workflows would increase knowledge about and acceptability of genomic medicine in primary care. This study contributes to the evidence base that knowledge of genetic risk in primary care may affect processes and outcomes of care.</p>
              <p>To date, the optimal way to return genetic results to patients with common diseases in primary care settings is not clear. Genetic counselors have been on the front line of delivering genetic testing results to patients and clinicians regarding mendelian disorders, but PCPs are on the front line of health care for most patients. Genetic counselors are a limited resource<sup><xref rid="zoi220058r37" ref-type="bibr">37</xref></sup> and may not be critical in returning results for chronic disease risk. Our stakeholders and formative research<sup><xref rid="zoi220058r27" ref-type="bibr">27</xref>,<xref rid="zoi220058r38" ref-type="bibr">38</xref></sup> guided us to have patients tested and receive results in their primary care practices via laypersons who were mainly of African ancestry and trained by genetic counselors to return results and by local stakeholders to be sensitive to the culture and challenges facing patients. We did not rely on PCPs to return test results because they did not order the test and did not feel prepared to return results,<sup><xref rid="zoi220058r39" ref-type="bibr">39</xref></sup> but we provided them with decision support to discuss results with their patients. This approach was well received by the patients; none chose to meet with a genetic counselor, although we offered the opportunity to all, and they viewed disclosure of results very favorably. Clinician extenders (nurse practitioners and physician assistants) may be useful for other practices to consider to permanently fill this role for busy clinicians or as a bridge while clinicians learn to incorporate information from a relatively new field into their workflow.</p>
              <sec id="H2-11-ZOI220058">
                <title>Limitations</title>
                <p>The study has some limitations. We excluded patients with CKD, and it is important to study the effects of genetic testing and disclosure of results on patients with abnormal kidney function. Our intervention had a modest effect size, possibly owing to increase in medication use and/or lifestyle change, which may have substantial benefits at the population level. However, interventions with more robust components and repeated reminders may demonstrate a more significant effect. Our primary outcome was within the intervention group, although we did see effects when comparing patients with high-risk <italic>APOL1</italic> genotypes vs controls. In addition, we did not have comprehensive data on lifestyle and dietary intake or medication refill data. In this pilot trial, the period of outcome assessment was short (1 year). However, this trial has informed a national multicenter trial called GUARDD-US, which is ongoing. We used change in SBP as a primary outcome because of prior strong associations with cardiovascular disease.<sup><xref rid="zoi220058r40" ref-type="bibr">40</xref></sup> However, diastolic BP is an important risk factor and will be explored in future work. We did not have information on treatment fidelity collected as part of the study protocol, and we did not have significant information on the type and dosage of medication and could only address the changes in broad groups. The upcoming GUARDD-US trial will address these issues in more detail. Confounding (including lifestyle factors, kidney function, and severity and treatment of hypertension) could affect these results. Finally, although we conducted this trial in academic, clinical, and primary care settings, we did so in 1 urban area, and it will be important to validate the findings in other settings.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI220058">
              <title>Conclusions</title>
              <p>Return of <italic>APOL1</italic> genetic testing results combined with EHR-based clinical decision support and disclosure of results to patients using laypersons improved SBP control and increased guideline-appropriate kidney function testing. These results may support an approach of broad implementation of genetic medicine in primary care. This broad implementation will benefit racial and ethnic minority groups that have been traditionally underrepresented in both clinical trials and genetic studies.<sup><xref rid="zoi220058r41" ref-type="bibr">41</xref></sup> Because it is imperative not to overlook the importance of social determinants of health in affecting chronic disease, it will also be important to understand and address the intersection of social and biological determinants in patient health.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI220058">
              <title>References</title>
              <ref id="zoi220058r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Albertus</surname><given-names>P</given-names></string-name>, <string-name><surname>Morgenstern</surname><given-names>H</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>B</given-names></string-name>, <string-name><surname>Saran</surname><given-names>R</given-names></string-name></person-group>. <article-title>Risk of ESRD in the United States</article-title>. <source>Am J Kidney Dis</source>. <year>2016</year>;<volume>68</volume>(<issue>6</issue>):<fpage>862</fpage>-<lpage>872</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2016.05.030</pub-id><?supplied-pmid 27578184?><pub-id pub-id-type="pmid">27578184</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McClellan</surname><given-names>W</given-names></string-name>, <string-name><surname>Tuttle</surname><given-names>E</given-names></string-name>, <string-name><surname>Issa</surname><given-names>A</given-names></string-name></person-group>. <article-title>Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension</article-title>. <source>Am J Kidney Dis</source>. <year>1988</year>;<volume>12</volume>(<issue>4</issue>):<fpage>285</fpage>-<lpage>290</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0272-6386(88)80221-X</pub-id><?supplied-pmid 3263042?><pub-id pub-id-type="pmid">3263042</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Myers</surname><given-names>OB</given-names></string-name>, <string-name><surname>Pankratz</surname><given-names>VS</given-names></string-name>, <string-name><surname>Norris</surname><given-names>KC</given-names></string-name>, <string-name><surname>Vassalotti</surname><given-names>JA</given-names></string-name>, <string-name><surname>Unruh</surname><given-names>ML</given-names></string-name>, <string-name><surname>Argyropoulos</surname><given-names>C</given-names></string-name></person-group>. <article-title>Surveillance of CKD epidemiology in the US—a joint analysis of NHANES and KEEP</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>15900</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-34233-w</pub-id><?supplied-pmid 30367154?><pub-id pub-id-type="pmid">30367154</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Genovese</surname><given-names>G</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>MD</given-names></string-name>, <etal/></person-group>. <article-title>Association of trypanolytic ApoL1 variants with kidney disease in African Americans</article-title>. <source>Science</source>. <year>2010</year>;<volume>329</volume>(<issue>5993</issue>):<fpage>841</fpage>-<lpage>845</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1193032</pub-id><?supplied-pmid 20647424?><pub-id pub-id-type="pmid">20647424</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Parsa</surname><given-names>A</given-names></string-name>, <string-name><surname>Kao</surname><given-names>WHL</given-names></string-name>, <string-name><surname>Xie</surname><given-names>D</given-names></string-name>, <etal/>; <collab>AASK Study Investigators</collab>; <collab>CRIC Study Investigators</collab></person-group>. <article-title><italic>APOL1</italic> risk variants, race, and progression of chronic kidney disease</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>23</issue>):<fpage>2183</fpage>-<lpage>2196</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1310345</pub-id><?supplied-pmid 24206458?><pub-id pub-id-type="pmid">24206458</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Foster</surname><given-names>MC</given-names></string-name>, <string-name><surname>Coresh</surname><given-names>J</given-names></string-name>, <string-name><surname>Fornage</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title><italic>APOL1</italic> variants associate with increased risk of CKD among African Americans</article-title>. <source>J Am Soc Nephrol</source>. <year>2013</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1484</fpage>-<lpage>1491</lpage>. doi:<pub-id pub-id-type="doi">10.1681/ASN.2013010113</pub-id><?supplied-pmid 23766536?><pub-id pub-id-type="pmid">23766536</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Fedick</surname><given-names>A</given-names></string-name>, <string-name><surname>Wasserman</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Analytical validation of a personalized medicine <italic>APOL1</italic> genotyping assay for nondiabetic chronic kidney disease risk assessment</article-title>. <source>J Mol Diagn</source>. <year>2016</year>;<volume>18</volume>(<issue>2</issue>):<fpage>260</fpage>-<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmoldx.2015.11.003</pub-id><?supplied-pmid 26773863?><pub-id pub-id-type="pmid">26773863</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rosset</surname><given-names>S</given-names></string-name>, <string-name><surname>Tzur</surname><given-names>S</given-names></string-name>, <string-name><surname>Behar</surname><given-names>DM</given-names></string-name>, <string-name><surname>Wasser</surname><given-names>WG</given-names></string-name>, <string-name><surname>Skorecki</surname><given-names>K</given-names></string-name></person-group>. <article-title>The population genetics of chronic kidney disease: insights from the <italic>MYH9</italic>-<italic>APOL1</italic> locus</article-title>. <source>Nat Rev Nephrol</source>. <year>2011</year>;<volume>7</volume>(<issue>6</issue>):<fpage>313</fpage>-<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrneph.2011.52</pub-id><?supplied-pmid 21537348?><pub-id pub-id-type="pmid">21537348</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <string-name><surname>Murea</surname><given-names>M</given-names></string-name></person-group>. <article-title>Target organ damage in African American hypertension: role of <italic>APOL1</italic></article-title>. <source>Curr Hypertens Rep</source>. <year>2012</year>;<volume>14</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11906-011-0237-4</pub-id><?supplied-pmid 22068337?><pub-id pub-id-type="pmid">22068337</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cooper</surname><given-names>RS</given-names></string-name>, <string-name><surname>Nadkarni</surname><given-names>GN</given-names></string-name>, <string-name><surname>Ogedegbe</surname><given-names>G</given-names></string-name></person-group>. <article-title>Race, ancestry, and reporting in medical journals</article-title>. <source>JAMA</source>. <year>2018</year>;<volume>320</volume>(<issue>15</issue>):<fpage>1531</fpage>-<lpage>1532</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2018.10960</pub-id><?supplied-pmid 30264132?><pub-id pub-id-type="pmid">30264132</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nadkarni</surname><given-names>GN</given-names></string-name>, <string-name><surname>Horowitz</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Genomics in CKD: is this the path forward?</article-title><source>Adv Chronic Kidney Dis</source>. <year>2016</year>;<volume>23</volume>(<issue>2</issue>):<fpage>120</fpage>-<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ackd.2016.01.017</pub-id><?supplied-pmid 26979150?><pub-id pub-id-type="pmid">26979150</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Franceschini</surname><given-names>N</given-names></string-name>, <string-name><surname>Frick</surname><given-names>A</given-names></string-name>, <string-name><surname>Kopp</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Genetic testing in clinical settings</article-title>. <source>Am J Kidney Dis</source>. <year>2018</year>;<volume>72</volume>(<issue>4</issue>):<fpage>569</fpage>-<lpage>581</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2018.02.351</pub-id><?supplied-pmid 29655499?><pub-id pub-id-type="pmid">29655499</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rasmussen-Torvik</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Stallings</surname><given-names>SC</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>AS</given-names></string-name>, <etal/></person-group>. <article-title>Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems</article-title>. <source>Clin Pharmacol Ther</source>. <year>2014</year>;<volume>96</volume>(<issue>4</issue>):<fpage>482</fpage>-<lpage>489</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.2014.137</pub-id><?supplied-pmid 24960519?><pub-id pub-id-type="pmid">24960519</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Judd</surname><given-names>E</given-names></string-name>, <string-name><surname>Calhoun</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Management of hypertension in CKD: beyond the guidelines</article-title>. <source>Adv Chronic Kidney Dis</source>. <year>2015</year>;<volume>22</volume>(<issue>2</issue>):<fpage>116</fpage>-<lpage>122</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ackd.2014.12.001</pub-id><?supplied-pmid 25704348?><pub-id pub-id-type="pmid">25704348</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gu</surname><given-names>A</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Desai Raj</surname><given-names>P</given-names></string-name></person-group>, Argulian E. <article-title>Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2017</year>;<volume>10</volume>(<issue>1</issue>):<elocation-id>e003166</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.116.003166</pub-id><?supplied-pmid 28096206?><pub-id pub-id-type="pmid">28096206</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nadkarni</surname><given-names>GN</given-names></string-name>, <string-name><surname>Gottesman</surname><given-names>O</given-names></string-name>, <string-name><surname>Linneman</surname><given-names>JG</given-names></string-name>, <etal/></person-group>. Development and validation of an electronic phenotyping algorithm for chronic kidney disease. <source>AMIA Annu Symp Proc</source>. 2014;2014:907-916. <?supplied-pmid 25954398?><pub-id pub-id-type="pmid">25954398</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ku</surname><given-names>E</given-names></string-name>, <string-name><surname>Lipkowitz</surname><given-names>MS</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <etal/></person-group>. <article-title>Strict blood pressure control associates with decreased mortality risk by APOL1 genotype</article-title>. <source>Kidney Int</source>. <year>2017</year>;<volume>91</volume>(<issue>2</issue>):<fpage>443</fpage>-<lpage>450</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.kint.2016.09.033</pub-id><?supplied-pmid 27927600?><pub-id pub-id-type="pmid">27927600</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kharbanda</surname><given-names>EO</given-names></string-name>, <string-name><surname>Asche</surname><given-names>SE</given-names></string-name>, <string-name><surname>Sinaiko</surname><given-names>AR</given-names></string-name>, <etal/></person-group>. <article-title>Clinical decision support for recognition and management of hypertension: a randomized trial</article-title>. <source>Pediatrics</source>. <year>2018</year>;<volume>141</volume>(<issue>2</issue>):<elocation-id>e20172954</elocation-id>. doi:<pub-id pub-id-type="doi">10.1542/peds.2017-2954</pub-id><?supplied-pmid 29371241?><pub-id pub-id-type="pmid">29371241</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Samal</surname><given-names>L</given-names></string-name>, <string-name><surname>Lipsitz</surname><given-names>SR</given-names></string-name>, <string-name><surname>Hicks</surname><given-names>LS</given-names></string-name></person-group>. <article-title>Impact of electronic health records on racial and ethnic disparities in blood pressure control at US primary care visits</article-title>. <source>Arch Intern Med</source>. <year>2012</year>;<volume>172</volume>(<issue>1</issue>):<fpage>75</fpage>-<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinternmed.2011.604</pub-id><?supplied-pmid 22232153?><pub-id pub-id-type="pmid">22232153</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Amόrtegui</surname><given-names>D</given-names></string-name>, <string-name><surname>Blancas</surname><given-names>I</given-names></string-name>, <string-name><surname>Wicklund</surname><given-names>C</given-names></string-name>, <string-name><surname>Friedewald</surname><given-names>J</given-names></string-name>, <string-name><surname>Sharp</surname><given-names>RR</given-names></string-name></person-group>. <article-title>African American living donors’ attitudes about <italic>APOL1</italic> genetic testing: a mixed methods study</article-title>. <source>Am J Kidney Dis</source>. <year>2018</year>;<volume>72</volume>(<issue>6</issue>):<fpage>819</fpage>-<lpage>833</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2018.07.017</pub-id><?supplied-pmid 30360961?><pub-id pub-id-type="pmid">30360961</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <string-name><surname>Moxey-Mims</surname><given-names>M</given-names></string-name></person-group>. <article-title>The <italic>APOL1</italic> Long-Term Kidney Transplantation Outcomes Network—APOLLO</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2018</year>;<volume>13</volume>(<issue>6</issue>):<fpage>940</fpage>-<lpage>942</lpage>. doi:<pub-id pub-id-type="doi">10.2215/CJN.01510218</pub-id><?supplied-pmid 29703792?><pub-id pub-id-type="pmid">29703792</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Horowitz</surname><given-names>CR</given-names></string-name>, <string-name><surname>Abul-Husn</surname><given-names>NS</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry</article-title>. <source>Contemp Clin Trials</source>. <year>2016</year>;47:101-108. doi:<pub-id pub-id-type="doi">10.1016/j.cct.2015.12.020</pub-id><?supplied-pmid 26747051?><pub-id pub-id-type="pmid">26747051</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r23">
                <label>23</label>
                <mixed-citation publication-type="webpage">Equator Network. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Accessed December 13, 2021. <ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">https://www.equator-network.org/reporting-guidelines/consort/</ext-link></mixed-citation>
              </ref>
              <ref id="zoi220058r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pickering</surname><given-names>TG</given-names></string-name>, <string-name><surname>Hall</surname><given-names>JE</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <etal/>; <collab>Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research</collab></person-group>. <article-title>Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research</article-title>. <source>Hypertension</source>. <year>2005</year>;<volume>45</volume>(<issue>1</issue>):<fpage>142</fpage>-<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.HYP.0000150859.47929.8e</pub-id><?supplied-pmid 15611362?><pub-id pub-id-type="pmid">15611362</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r25">
                <label>25</label>
                <mixed-citation publication-type="webpage">Agency for Healthcare Research and Quality. The SHARE approach. Accessed December 3, 2018. <ext-link xlink:href="https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html" ext-link-type="uri">https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html</ext-link></mixed-citation>
              </ref>
              <ref id="zoi220058r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gottesman</surname><given-names>O</given-names></string-name>, <string-name><surname>Scott</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>SB</given-names></string-name>, <etal/></person-group>. <article-title>The CLIPMERGE PGx program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics</article-title>. <source>Clin Pharmacol Ther</source>. <year>2013</year>;<volume>94</volume>(<issue>2</issue>):<fpage>214</fpage>-<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.2013.72</pub-id><?supplied-pmid 23588317?><pub-id pub-id-type="pmid">23588317</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Horowitz</surname><given-names>CR</given-names></string-name>, <string-name><surname>Ferryman</surname><given-names>K</given-names></string-name>, <string-name><surname>Negron</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Race, genomics and chronic disease: what patients with African ancestry have to say</article-title>. <source>J Health Care Poor Underserved</source>. <year>2017</year>;<volume>28</volume>(<issue>1</issue>):<fpage>248</fpage>-<lpage>260</lpage>. doi:<pub-id pub-id-type="doi">10.1353/hpu.2017.0020</pub-id><?supplied-pmid 28238999?><pub-id pub-id-type="pmid">28238999</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r28">
                <label>28</label>
                <mixed-citation publication-type="journal">Horowitz CR, Sabin T, Ramos M, et al. Successful recruitment and retention of diverse participants in a genomics clinical trial: a good invitation to a great party. <source>Genet Med</source>. 2019;21(10):2364-2370. doi:<pub-id pub-id-type="doi">10.1038/s41436-019-0498-x</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McClellan</surname><given-names>WM</given-names></string-name>, <string-name><surname>Langston</surname><given-names>RD</given-names></string-name>, <string-name><surname>Presley</surname><given-names>R</given-names></string-name></person-group>. <article-title>Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease</article-title>. <source>J Am Soc Nephrol</source>. <year>2004</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1912</fpage>-<lpage>1919</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.ASN.0000129982.10611.4C</pub-id><?supplied-pmid 15213281?><pub-id pub-id-type="pmid">15213281</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McClellan</surname><given-names>W</given-names></string-name>, <string-name><surname>Warnock</surname><given-names>DG</given-names></string-name>, <string-name><surname>McClure</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study</article-title>. <source>J Am Soc Nephrol</source>. <year>2006</year>;<volume>17</volume>(<issue>6</issue>):<fpage>1710</fpage>-<lpage>1715</lpage>. doi:<pub-id pub-id-type="doi">10.1681/ASN.2005111200</pub-id><?supplied-pmid 16641151?><pub-id pub-id-type="pmid">16641151</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Matsushita</surname><given-names>K</given-names></string-name>, <string-name><surname>van der Velde</surname><given-names>M</given-names></string-name>, <string-name><surname>Astor</surname><given-names>BC</given-names></string-name>, <etal/>; <collab>Chronic Kidney Disease Prognosis Consortium</collab></person-group>. <article-title>Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9731</issue>):<fpage>2073</fpage>-<lpage>2081</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60674-5</pub-id><?supplied-pmid 20483451?><pub-id pub-id-type="pmid">20483451</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Malhotra</surname><given-names>R</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>HA</given-names></string-name>, <string-name><surname>Benavente</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis</article-title>. <source>JAMA Intern Med</source>. <year>2017</year>;<volume>177</volume>(<issue>10</issue>):<fpage>1498</fpage>-<lpage>1505</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2017.4377</pub-id><?supplied-pmid 28873137?><pub-id pub-id-type="pmid">28873137</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nadkarni</surname><given-names>GN</given-names></string-name>, <string-name><surname>Galarneau</surname><given-names>G</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>SB</given-names></string-name>, <etal/></person-group>. <article-title>Apolipoprotein L1 variants and blood pressure traits in African Americans</article-title>. <source>J Am Coll Cardiol</source>. <year>2017</year>;<volume>69</volume>(<issue>12</issue>):<fpage>1564</fpage>-<lpage>1574</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2017.01.040</pub-id><?supplied-pmid 28335839?><pub-id pub-id-type="pmid">28335839</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hollands</surname><given-names>GJ</given-names></string-name>, <string-name><surname>French</surname><given-names>DP</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>SJ</given-names></string-name>, <etal/></person-group>. <article-title>The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis</article-title>. <source>BMJ</source>. <year>2016</year>;<volume>352</volume>:<fpage>i1102</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.i1102</pub-id><?supplied-pmid 26979548?><pub-id pub-id-type="pmid">26979548</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bloss</surname><given-names>CS</given-names></string-name>, <string-name><surname>Schork</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Topol</surname><given-names>EJ</given-names></string-name></person-group>. <article-title>Effect of direct-to-consumer genomewide profiling to assess disease risk</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>6</issue>):<fpage>524</fpage>-<lpage>534</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1011893</pub-id><?supplied-pmid 21226570?><pub-id pub-id-type="pmid">21226570</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Larson</surname><given-names>EA</given-names></string-name>, <string-name><surname>Wilke</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Integration of genomics in primary care</article-title>. <source>Am J Med</source>. <year>2015</year>;<volume>128</volume>(<issue>11</issue>):<fpage>1251.e1</fpage>-<lpage>1251.e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjmed.2015.05.011</pub-id><?supplied-pmid 26031886?><pub-id pub-id-type="pmid">26031886</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoskovec</surname><given-names>JM</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>RL</given-names></string-name>, <string-name><surname>Carey</surname><given-names>ME</given-names></string-name>, <etal/></person-group>. <article-title>Projecting the supply and demand for certified genetic counselors: a workforce study</article-title>. <source>J Genet Couns</source>. <year>2018</year>;<volume>27</volume>(<issue>1</issue>):<fpage>16</fpage>-<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10897-017-0158-8</pub-id><?supplied-pmid 29052810?><pub-id pub-id-type="pmid">29052810</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaplan</surname><given-names>B</given-names></string-name>, <string-name><surname>Caddle-Steele</surname><given-names>C</given-names></string-name>, <string-name><surname>Chisholm</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>A culture of understanding: reflections and suggestions from a genomics research community board</article-title>. <source>Prog Community Health Partnersh</source>. <year>2017</year>;<volume>11</volume>(<issue>2</issue>):<fpage>161</fpage>-<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1353/cpr.2017.0020</pub-id><?supplied-pmid 28736408?><pub-id pub-id-type="pmid">28736408</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hauser</surname><given-names>D</given-names></string-name>, <string-name><surname>Obeng</surname><given-names>AO</given-names></string-name>, <string-name><surname>Fei</surname><given-names>K</given-names></string-name>, <string-name><surname>Ramos</surname><given-names>MA</given-names></string-name>, <string-name><surname>Horowitz</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Views of primary care providers on testing patients for genetic risks for common chronic diseases</article-title>. <source>Health Aff (Millwood)</source>. <year>2018</year>;<volume>37</volume>(<issue>5</issue>):<fpage>793</fpage>-<lpage>800</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2017.1548</pub-id><?supplied-pmid 29733703?><pub-id pub-id-type="pmid">29733703</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kannel</surname><given-names>WB</given-names></string-name></person-group>. <article-title>Elevated systolic blood pressure as a cardiovascular risk factor</article-title>. <source>Am J Cardiol</source>. <year>2000</year>;<volume>85</volume>(<issue>2</issue>):<fpage>251</fpage>-<lpage>255</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0002-9149(99)00635-9</pub-id><?supplied-pmid 10955386?><pub-id pub-id-type="pmid">10955386</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220058r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Popejoy</surname><given-names>AB</given-names></string-name>, <string-name><surname>Fullerton</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Genomics is failing on diversity</article-title>. <source>Nature</source>. <year>2016</year>;<volume>538</volume>(<issue>7624</issue>):<fpage>161</fpage>-<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1038/538161a</pub-id><?supplied-pmid 27734877?><pub-id pub-id-type="pmid">27734877</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI220058-1">
              <supplementary-material id="note-ZOI220058-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e221048-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e221048-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
